On 14 December 2015, orphan designation (EU/3/15/1584) was granted by the European Commission to Diamond BioPharm Limited, United Kingdom, for variant of recombinant human fibroblast growth factor 19 for the treatment of primary sclerosing cholangitis.
The sponsorship was transferred to Diamond ROC EOOD, Bulgaria, in March 2019.
The sponsorship was transferred to Diamond Pharma Services Ireland Limited in February 2020.
Variant of recombinant human fibroblast growth factor 19
|Disease / condition||
Treatment of primary sclerosing cholangitis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.